Live Oak Private Wealth LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,771 shares of the company’s stock after selling 93 shares during the quarter. Live Oak Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the company. Nordwand Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $785,273,000. Savant Capital LLC increased its stake in Johnson & Johnson by 8,568.8% in the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock valued at $29,637,000 after acquiring an additional 3,588,251 shares during the last quarter. Edmp Inc. increased its stake in Johnson & Johnson by 17,222.9% in the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock valued at $18,247,000 after acquiring an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. increased its stake in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares during the last quarter. Finally, GQG Partners LLC increased its stake in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after acquiring an additional 2,547,378 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
JNJ has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Piper Sandler reduced their price objective on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Atlantic Securities dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Finally, StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same quarter last year, the firm earned $2.67 earnings per share. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.
Insider Buying and Selling at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.